ClinicalTrials.gg
CompletedNCT04495478Updated Feb 14, 2023Results posted

A Study of Ramucirumab (LY3009806) in Healthy Participants

A Phase 1 interventional study of Ramucirumab - IV and Placebo - IV in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-02-14.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This study evaluates a new formulation of ramucirumab, a drug approved for several types of cancer.

In this study of healthy participants, a small amount of ramucirumab will be given by injection either into a vein or just under the skin. Study doctors will measure the amount of ramucirumab in the bloodstream.

Side effects and tolerability will be documented. The study will last for about 16 weeks for each participant, including screening and follow up. Screening is required within 28 days prior to entering the study.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Overtly healthy male or a female (not pregnant and agreeable to take measures until study completion)
  • Have a body weight greater than or equal to (≥)70 kilograms (kg) and (BMI) of 18 to 32 kilogram per square meter (kg/m ²), inclusive
  • Have normal blood pressure, pulse rate, (ECG), and blood and urine laboratory test results that are acceptable for the study

Exclusion criteria

Exclusion Criteria:

  • Are currently participating in or completed a clinical trial within the last 30 days or any other type of medical research judged to be incompatible with this study
  • Have previously participated or withdrawn from this study
  • Have or used to have health problems or laboratory test results or readings that, in the opinion of the doctor, could make it unsafe to participate, or could interfere with understanding the results of the study
  • Had blood loss of more than 500 milliliters (mL) within the previous 30 days of study screening
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Placebo - Intravenous (IV)

    Participants received single dose of placebo administered IV.

    Drug: Placebo - IV

  • Placebo comparator
    350 mg Ramucirumab IV

    Participants received single 350 milligram (mg) ramucirumab administered as a 60-minute intravenous infusion at a concentration of 10 milligram per millilitre (mg/mL) as one 35 mL infusion.

    Drug: Ramucirumab - IV

  • Experimental
    Placebo - Subcutaneous (SC)

    Participants received single dose of placebo administered SC.

    Drug: Placebo - SC

  • Placebo comparator
    350 mg Ramucirumab SC (1x2 mL)

    Participants received single 350 mg ramucirumab SC administered at a concentration of 175 mg/mL as one 2 mL injection.

    Drug: Ramucirumab - SC

  • Experimental
    350 mg Ramucirumab SC (2x2 mL)

    Participants received single 350 mg ramucirumab SC administered at a concentration of 87.5 mg/mL as two 2 mL injections.

    Drug: Ramucirumab - SC

  • Experimental
    350 mg Ramucirumab SC (2x1 mL)

    Participants received single 350 mg ramucirumab SC administered at a concentration of 175 mg/mL as two 1 mL injections.

    Drug: Ramucirumab - SC

  • Experimental
    700 mg Ramucirumab SC (2x2 mL)

    Participants received single 700 mg ramucirumab SC administered at a concentration of 175 mg/mL as two 2 mL injections.

    Drug: Ramucirumab - SC

Interventions

  • DrugRamucirumab - IV

    Administered IV.

    Also known as: LY3009806

  • DrugPlacebo - IV

    Administered IV.

  • Administered SC.

    Also known as: LY3009806

  • DrugPlacebo - SC

    Administered SC.

06

What researchers measure

Primary outcomes

  1. Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    An SAE is any adverse event from this study that results in 1 of the following: Death, initial or prolonged inpatient hospitalization, a life-threatening experience (that is, risk of death), persistent or significant disability/incapacity, congenital anomaly/birth defect, Important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the subject or may require intervention to prevent 1 of the other outcomes listed in the definition above. The number of participants with one or more SAEs considered by the investigator to be related to study drug administration is reported. A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module

    Time frame: Baseline through Day 90

  2. Number of Participants With Injection Site Reactions (ISRs) Following Subcutaneous (SC) Administration of Study Drug

    Number of participants showing ISRs when the drug was administered subcutaneously were reported.

    Time frame: Day 1 Predose through Day 90

  3. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of Ramucirumab

    PK: AUC\[0-∞\] of Ramucirumab.

    Time frame: 1, 8, 24, 48, 72, 96, 120, 144, 168, 264, 336, 504 hours post-dose

  4. PK: Maximum Concentration (Cmax) of Ramucirumab

    PK: Cmax of Ramucirumab

    Time frame: 1, 8, 24, 48, 72, 96, 120, 144, 168, 264, 336, 504 hours post-dose

07

Results

Posted Feb 14, 2023

Participant flow

Participant flow — Overall Study
MilestonePlacebo IV350 mg Ramucirumab IVPlacebo SC350 mg Ramucirumab SC (1x2 mL)350 mg Ramucirumab SC (2x2 mL)350 mg Ramucirumab SC (2x1 mL)700 mg Ramucirumab SC (2x2 mL)
Started37127777
Received at least one dose of study drug37127777
Completed36126677
Not completed0101100
Withdrew: Withdrawal by subject0001000
Withdrew: Physician decision0100100

Outcome measures

PrimaryNumber of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

An SAE is any adverse event from this study that results in 1 of the following: Death, initial or prolonged inpatient hospitalization, a life-threatening experience (that is, risk of death), persistent or significant disability/incapacity, congenital anomaly/birth defect, Important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the subject or may require intervention to prevent 1 of the other outcomes listed in the definition above. The number of participants with one or more SAEs considered by the investigator to be related to study drug administration is reported. A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module

Time frame:
Baseline through Day 90
Reported as:
Count of participants · Participants
Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
ParticipantsPlacebo IV350 mg Ramucirumab IVPlacebo SC350 mg Ramucirumab SC (1x2 mL)350 mg Ramucirumab SC (2x2 mL)350 mg Ramucirumab SC (2x1 mL)700 mg Ramucirumab SC (2x2 mL)
Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration0010100
PrimaryNumber of Participants With Injection Site Reactions (ISRs) Following Subcutaneous (SC) Administration of Study Drug

Number of participants showing ISRs when the drug was administered subcutaneously were reported.

Time frame:
Day 1 Predose through Day 90
Reported as:
Count of participants · Participants
Number of Participants With Injection Site Reactions (ISRs) Following Subcutaneous (SC) Administration of Study Drug
ParticipantsPlacebo SC350 mg Ramucirumab SC (1x2 mL)350 mg Ramucirumab SC (2x2 mL)350 mg Ramucirumab SC (2x1 mL)700 mg Ramucirumab SC (2x2 mL)
Number of Participants With Injection Site Reactions (ISRs) Following Subcutaneous (SC) Administration of Study Drug33211
PrimaryPharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of Ramucirumab

PK: AUC\[0-∞\] of Ramucirumab.

Time frame:
1, 8, 24, 48, 72, 96, 120, 144, 168, 264, 336, 504 hours post-dose
Reported as:
Geometric mean · hour*microgram per milliliter (h*μg/mL)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of Ramucirumab
hour*microgram per milliliter (h*μg/mL)350 mg Ramucirumab IV350 mg Ramucirumab SC (1x2 mL)350 mg Ramucirumab SC (2x2 mL)350 mg Ramucirumab SC (2x1 mL)700 mg Ramucirumab SC (2x2 mL)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of Ramucirumab18700 ± 195250 ± 485140 ± 766350 ± 5714200 ± 76
PrimaryPK: Maximum Concentration (Cmax) of Ramucirumab

PK: Cmax of Ramucirumab

Time frame:
1, 8, 24, 48, 72, 96, 120, 144, 168, 264, 336, 504 hours post-dose
Reported as:
Geometric mean · μg/mL
PK: Maximum Concentration (Cmax) of Ramucirumab
μg/mL350 mg Ramucirumab IV350 mg Ramucirumab SC (1x2 mL)350 mg Ramucirumab SC (2x2 mL)350 mg Ramucirumab SC (2x1 mL)700 mg Ramucirumab SC (2x2 mL)
PK: Maximum Concentration (Cmax) of Ramucirumab116 ± 1124 ± 5620.2 ± 6321 ± 6646.7 ± 44

Adverse events

Collected over Baseline up to Day 90. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo IV0/3 (0%)0/3 (0%)1/3 (33.3%)
350 mg Ramucirumab IV0/7 (0%)0/7 (0%)4/7 (57.1%)
Placebo SC0/12 (0%)1/12 (8.3%)1/12 (8.3%)
350 mg Ramucirumab SC (1x2 mL)0/7 (0%)0/7 (0%)3/7 (42.9%)
350 mg Ramucirumab SC (2x2 mL)0/7 (0%)1/7 (14.3%)2/7 (28.6%)
350 mg Ramucirumab SC (2x1 mL)0/7 (0%)0/7 (0%)5/7 (71.4%)
700 mg Ramucirumab SC (2x2 mL)0/7 (0%)0/7 (0%)4/7 (57.1%)
Most frequent serious events
Most frequent serious events
EventPlacebo IV350 mg Ramucirumab IVPlacebo SC350 mg Ramucirumab SC (1x2 mL)350 mg Ramucirumab SC (2x2 mL)350 mg Ramucirumab SC (2x1 mL)700 mg Ramucirumab SC (2x2 mL)
Peritonsillar abscessInfections and infestations0/30/70/120/71/70/70/7
Pharyngitis streptococcalInfections and infestations0/30/70/120/71/70/70/7
TonsillitisInfections and infestations0/30/70/120/71/70/70/7
Alcohol withdrawal syndromePsychiatric disorders0/30/71/120/70/70/70/7
Most frequent other events
Showing 10 of 21
Most frequent other events
EventPlacebo IV350 mg Ramucirumab IVPlacebo SC350 mg Ramucirumab SC (1x2 mL)350 mg Ramucirumab SC (2x2 mL)350 mg Ramucirumab SC (2x1 mL)700 mg Ramucirumab SC (2x2 mL)
HeadacheNervous system disorders0/34/71/120/71/70/72/7
HyperhidrosisSkin and subcutaneous tissue disorders1/30/70/120/70/70/70/7
Excessive cerumen productionEar and labyrinth disorders0/30/70/121/70/70/70/7
Aphthous ulcerGastrointestinal disorders0/30/70/120/70/71/70/7
DiarrhoeaGastrointestinal disorders0/30/70/120/71/70/71/7
DyspepsiaGastrointestinal disorders0/31/70/120/70/70/70/7
NauseaGastrointestinal disorders0/30/70/120/70/71/71/7
ToothacheGastrointestinal disorders0/31/70/120/70/70/70/7
Feeling hotGeneral disorders0/30/70/120/70/71/70/7
Injection site bruisingGeneral disorders0/30/70/120/70/71/70/7

Baseline characteristics

All participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Placebo IV350 mg Ramucirumab IVPlacebo SC350 mg Ramucirumab SC (1x2 mL)350 mg Ramucirumab SC (2x2 mL)350 mg Ramucirumab SC (2x1 mL)700 mg Ramucirumab SC (2x2 mL)Total
Median34 (28 to 53)35 (20 to 54)37 (21 to 58)51 (24 to 59)46 (26 to 56)39 (21 to 60)41 (22 to 53)40 (20 to 60)
Sex: Female, Male
Sex: Female, Male(Participants)Placebo IV350 mg Ramucirumab IVPlacebo SC350 mg Ramucirumab SC (1x2 mL)350 mg Ramucirumab SC (2x2 mL)350 mg Ramucirumab SC (2x1 mL)700 mg Ramucirumab SC (2x2 mL)Total
Female02222019
Male3510557641
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo IV350 mg Ramucirumab IVPlacebo SC350 mg Ramucirumab SC (1x2 mL)350 mg Ramucirumab SC (2x2 mL)350 mg Ramucirumab SC (2x1 mL)700 mg Ramucirumab SC (2x2 mL)Total
Hispanic or Latino237442123
Not Hispanic or Latino145335627
Unknown or Not Reported00000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo IV350 mg Ramucirumab IVPlacebo SC350 mg Ramucirumab SC (1x2 mL)350 mg Ramucirumab SC (2x2 mL)350 mg Ramucirumab SC (2x1 mL)700 mg Ramucirumab SC (2x2 mL)Total
American Indian or Alaska Native01100002
Asian00000000
Native Hawaiian or Other Pacific Islander00000000
Black or African American123022212
White248655535
More than one race00010001
Unknown or Not Reported00000000
Region of Enrollment
Region of Enrollment(Participants)Placebo IV350 mg Ramucirumab IVPlacebo SC350 mg Ramucirumab SC (1x2 mL)350 mg Ramucirumab SC (2x2 mL)350 mg Ramucirumab SC (2x1 mL)700 mg Ramucirumab SC (2x2 mL)Total
United States3712777750
08

Study locations

1 site
  • Covance Clinical Research Inc
    Daytona Beach, Florida 32117, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2020 to primary completion in May 2021, 9 months.

Results were first posted in Feb 2023, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2020
First posted
Jul 31, 2020
StartActual
Jul 30, 2020
Primary completionActual
May 9, 2021
CompletionActual
May 9, 2021
Results first posted
Feb 14, 2023
Last update
Feb 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04495478
Responsible party
Sponsor
First posted
Jul 31, 2020
Start date
Jul 30, 2020
Primary completion
May 9, 2021
Completion
May 9, 2021
Results posted
Feb 14, 2023
Last update
Feb 14, 2023

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ramucirumab

Start the discussion